LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Search

Legend Biotech Corp ADR

Chiusa

SettoreSettore sanitario

16.72 -4.07

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

16.71

Massimo

17.65

Metriche Chiave

By Trading Economics

Entrata

8.1M

-31M

Vendite

35M

308M

Margine di Profitto

-10.06

Dipendenti

2,900

EBITDA

25M

-7.7M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+212.81% upside

Dividendi

By Dow Jones

Utili prossimi

12 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-348M

3.2B

Apertura precedente

20.79

Chiusura precedente

16.72

Notizie sul Sentiment di mercato

By Acuity

100%

0%

324 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Legend Biotech Corp ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 mar 2026, 17:10 UTC

Acquisizioni, Fusioni, Takeovers

Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets -- Barrons.com

10 mar 2026, 11:01 UTC

Utili

Legend Biotech 4Q Adj EPS 1c >LEGN

10 mar 2026, 11:01 UTC

Utili

Legend Biotech 4Q Loss/Shr 8c >LEGN

10 mar 2026, 11:00 UTC

Utili

Legend Biotech 4Q Research and Development Expenses $101.3M >LEGN

10 mar 2026, 11:00 UTC

Utili

Legend Biotech 4Q Rev $306.3M >LEGN

12 nov 2025, 12:10 UTC

Utili

Legend Biotech 3Q Adj Loss $18.8M >LEGN

12 nov 2025, 12:01 UTC

Utili

Legend Biotech 3Q Loss/Shr 11c >LEGN

12 nov 2025, 12:00 UTC

Utili

Legend Biotech 3Q Rev $272.3M >LEGN

11 ago 2025, 11:06 UTC

Utili

Legend Biotech 2Q Loss/Shr 34c >LEGN

11 ago 2025, 11:06 UTC

Utili

Legend Biotech 2Q Loss $125.4M >LEGN

11 ago 2025, 11:00 UTC

Utili

Legend Biotech 2Q Rev $255.1M >LEGN

13 mag 2025, 11:01 UTC

Utili

Legend Biotech 1Q Loss/Shr 27c >LEGN

13 mag 2025, 11:00 UTC

Utili

Legend Biotech 1Q Rev $195.1M >LEGN

Confronto tra pari

Modifica del prezzo

Legend Biotech Corp ADR Previsione

Obiettivo di Prezzo

By TipRanks

212.81% in crescita

Previsioni per 12 mesi

Media 54.71 USD  212.81%

Alto 80 USD

Basso 21 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Legend Biotech Corp ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

10

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.5 / 33.91Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
help-icon Live chat